Synchronized cycles of bacterial lysis for in vivo delivery
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The widespread view of bacteria as strictly pathogenic has given way to an appreciation of the prevalence of some beneficial microbes within the human body. It is perhaps inevitable that some bacteria would evolve to preferentially grow in environments that harbor disease and thus provide a natural platform for the development of engineered therapies. Such therapies could benefit from bacteria that are programmed to limit bacterial growth while continually producing and releasing cytotoxic agents in situ. Here we engineer a clinically relevant bacterium to lyse synchronously ata threshold population density and to release genetically encoded cargo. Following quorum lysis, a small number of surviving bacteria reseed the growing population, thus leading to pulsatile delivery cycles. We used microfluidic devices to characterize the engineered lysis strain and we demonstrate its potential as a drug delivery platform via co-culture with human cancer cells in vitro. Asa proof of principle, we tracked the bacterial population dynamics in ectopic syngeneic colorectal tumours in mice via a luminescent reporter. The lysis strain exhibits pulsatile population dynamics in vivo, with mean bacterial luminescence that remained two orders of magnitude lower than an unmodified strain. Finally, guided by previous findings that certain bacteria can enhance the efficacy of standard therapies, we orally administered the lysis strain alone or in combination with a clinical chemotherapeutic to a syngeneic mouse transplantation model of hepatic colorectal metastases. We found that the combination of both circuit-engineered bacteria and chemotherapy leads to a notable reduction of tumour activity along with a marked survival benefit over either therapy alone.Our approach establishes a methodology for leveraging the tools of synthetic biology to exploit the natural propensity for certain bacteria to colonize disease sites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An interesting general approach implements engineered bacterial lysis, which enables antitumor protein production or release only when a predefined population density of bacteria is reached (154–157).”
From The microbiome and human cancer (2021) · cites this paper as [155]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The human microbiome: at the interface of health and disease
Cho, I., & Blaser, M. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3182 · Cited by 3,449
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Garrett, W. S. (2015) · Science · doi:10.1126/science.aaa4972 · Cited by 1,404
A synchronized quorum of genetic clocks
Danino, T., Mondragón-Palomino, O., Tsimring, L., & Hasty, J. (2010) · Nature · doi:10.1038/nature08753 · Cited by 992
Self-citationLeone, V., Gibbons, S. M., Martinez, K., Hutchison, A. L., Huang, E. Y., Cham, C. M., Pierre, J. F., Heneghan, A. F., Nadimpalli, A., Hubert, N., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.03.006 · Cited by 911
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905 · cited 1×
“Thus a synergistic effect may arise when bacteria are used to deliver drugs to the necrotic core of a tumor, while standard chemotherapy is used for the vascularized regions 11,26 .”
BackgroundCombination bacteriolytic therapy for the treatment of experimental tumors
Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., & Vogelstein, B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251543698 · Cited by 563
Microbial Dysbiosis Is Associated with Human Breast Cancer
Xuan, C., Shamonki, J. M., Chung, A., DiNome, M. L., Chung, M., Sieling, P. A., & Lee, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083744 · Cited by 543
Tumor-targeted Salmonella as a novel anticancer vector.
Pawelek, J. M., Low, K. B., & Bermudes, D. G. (1997) · PubMed · Cited by 527
Programmable probiotics for detection of cancer in urine
Danino, T., Prindle, A., Kwong, G. A., Skalak, M., Li, H., Allen, K., Hasty, J., & Bhatia, S. N. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3519 · Cited by 467
Self-citation
Cited by
Items 701–782 of 782
Engineering self-organized criticality in living cellsPreprint
Vidiella, B., Guillamon, A., Sardanyés, J., Maull, V., Pueyo, N. C., & Solé, R. V. (2020) · Research Square · doi:10.21203/rs.3.rs-118874/v1 · Cited by 1
Belz, G. T. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736114961.793562924
Development of CRISPR-based programmable transcriptional regulators and their applications in plants
Selma, S. (2022) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/185046 · Cited by 1
Engineering Microbes for Smart Diagnostics and Lab-on-Chip
Srijaya, S., Patel, P., Verma, S. K., & Mishra, Y. K. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_5
Exploring the Potential of Microbial Engineering: The Prospect, Promise, and Essence
Patra, S. D., Arunima, A., & Suar, M. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_1
Affordable Therapeutics Through Engineered Microbes
Sahoo, S., & Misra, N. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_15
BIOLOGIA SINTÉTICA EM BACTÉRIAS: CONTROLANDO A EXPRESSÃO GÊNICA ATRAVÉS DA LUZ
Endo, A. K., Bonadio, D. T., Yepez, E. A. V., Alves, E. T. M., Ramella, G. M., & Park, J. H. (2023) · Editora Científica Digital eBooks · doi:10.37885/230111832 · Cited by 1
Biotecnologia Microbiana - Volume 1
da Silva, S. K. R., de Sousa, S. F., & de Santana, R. C. F. (2023) · Editora Científica Digital eBooks · doi:10.37885/978-65-5360-269-4
Synthetic Biology in Microbiology
Juhas, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-29544-7_7
Ultrasound-Visible Engineered Bacteria for Tumor Chem-ImmunotherapyPreprint
Yang, Y., Wang, Y., Zeng, F., Chen, Y., Chen, Z., & Yan, F. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4582895
Veteriner Bilimlerinde Probiyotiklerin Terapötik, Profilaktik ve Fonksiyonel Kullanımı
Karadağoğlu, Ö., Rıaz, R., Çıldır, Ö. Ş., Makav, M., Kaya, K., Küçükoflaz, M., AYDIN, E., Ölmez, M., Şahin, T., Sezer, M., et al. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub358
Helmint Kaynaklı Enfeksiyonların Kontrolünde Probiyotikler
Aydın, N., Ölmez, N., & Barış, S. A. R. I. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub358.c1524
Köpek ve Kedilerde Yeni Gelişmeler: Probiyotikler
Batı, Y. U., Sezer, M., & Akyüz, E. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub358.c1523
Obezitede Probiyotiklerin Glukoz ve Lipid Metabolizması Üzerine Etkisi
Aygörmez, S. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub358.c1526
Genetiği Değiştirilmiş Probiyotikler
Çıldır, Ö. Ş. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub358.c1516
Redefining Cancer Battlefields: Novel CAR T-cell Therapies in Solid Tumor Warfare
Yeh, A. C., & Markey, K. A. (2024) · The Hematologist · doi:10.1182/hem.v21.1.202413
Park, J. H., Holló, G., & Schaerli, Y. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.28.586779
Bacteria-Based Approach to Cancer Therapy
Bình, T. D., Bokorová, R., & Yamada, T. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_337 · Cited by 1
Chitosan-Based Hydrogels: Current Strategic Fabrication and Practical Application Perspectives
Vo, T. M. T., & Kobayashi, T. (2024) · Advances in chemical and materials engineering book series · doi:10.4018/979-8-3693-0003-9.ch008 · Cited by 1
Applications of Nanomaterial‐Microorganism Hybrid Systems in the Treatment of Tumor
Khan, M. S., Baig, M. A., Tian, M., Li, B., Feng, G., Yang, R., Bai, Y., & Zheng, B. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202400425 · Cited by 2
Kokarakis, E. J., Santos‐Merino, M., Ghaffarinasab, S., Vocelle, D. B., & Ducat, D. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.03.647055
Research progress on ultrasound in bacteria-mediated tumor treatment
Li, M., Kuang, C., Guo, Z., Du, M., & Chen, Z. (2025) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2025.2489476
Odah, M. (2025) · Preprints.org · doi:10.20944/preprints202505.1697.v1
Godonu, S. S. (2025) · IgMin Research · doi:10.61927/igmin310 · Cited by 2
A quasi-stationary distribution bound for fault analysis in gene regulatory networks
Cravo, F., Függer, M., & Nowak, T. (2026) · Journal of The Royal Society Interface · doi:10.1098/rsif.2025.1041
Synthetic biology and genetic engineering in pharmaceutical bioprospecting
Kant, S., Roy, S., & Sarkar, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33032-2.00019-8
How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace
Wright, J. A., & Woods, S. L. (2025) · doi:10.64628/aa.r9cugrp35
Proto‐Panic Modulation by Caffeine‐Proteinoid Complexes
Mougkogiannis, P., & Adamatzky, A. (2026) · Journal of Applied Polymer Science · doi:10.1002/app.71377
Chun, K., Stephens, K., Wang, S., Tsao, C.-Y., Payne, G. F., & Bentley, W. E. (2021) · Figshare · doi:10.6084/m9.figshare.17079392
Biohybrid miniature robots using living organisms
Zhang, M., Zhong, W., Chen, W., Wang, H., He, J., Liu, Z., Uthappa, U. T., Guo, Z., & Wang, B. (2026) · International Journal of Extreme Manufacturing · doi:10.1088/2631-7990/ae34f9
Live biotherapeutics in cancer therapy
Mishra, R., Kumar, S. S., Panda, T. S., Mahapatra, S., & Prasad, P. (2026) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2026.01.002 · Cited by 3
Advancements in technology for developing recombinant live biotherapeutics
Verma, J. K., & Paul, D. (2026) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2026.01.006 · Cited by 1
Control Theory for Diffusion-Based Molecular Communication Systems
Kotsuka, T., & Hori, Y. (2026) · Springer eBooks · doi:10.1007/978-981-95-2394-8_24
Aloma, E. R., Rodríguez, L. E., Ray, M., & Hoffmeister, B. (2026) · Research Square · doi:10.21203/rs.3.rs-8746034/v1
Toward development of soil-derived Bacillus isolates as lung cancer cytotoxic agents
Deb, D., Liguori, F., Shuster, B. M., Huang, R., Shoreibah, S., Wang, S. C., Ocampo, N. E. R., Murray, K. P., & Danino, T. (2026) · BioDesign Research · doi:10.1016/j.bidere.2026.100074
Self-citationMistretta, M. (2021) · theses.fr (ABES) · doi:10.70675/a814c67cz9630z40f6z8867z43d3267f3290
Production of magnetic bacteria and their use in biotechnology
Aubry, M. (2020) · theses.fr (ABES) · doi:10.70675/412befcbz4db8z4b6fz8752z9e544fa75305
Aditya, C. (2021) · theses.fr (ABES) · doi:10.70675/f72a0de8z9c92z4acfzb0c0z1849be9dcdcb
Design of Distributed Biological Circuits
Cravo, F. (2024) · theses.fr (ABES) · doi:10.70675/dccdb006z6bc5z4168zbf01z0da5a97efd81
Bian, X., Jiang, L., Xu, M., Sun, Y., Liu, X., Fan, T., Li, M., Cao, L., & Kong, Q. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04448-5
Li, M., Chen, X., Cao, L., Lei, M., Yuan, H., Bian, X., Sun, H., Yan, Z., Li, K., Liu, Q., et al. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.5c00952
Zhang, Z., Jiang, X., 黄文军, 杨小猛, & Li, F. F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1790215 · Cited by 1
Microbial therapeutic agents as a new frontier in tumor-targeted drug delivery
Islam, T., Ali, S., Almalki, M., & Rabbee, M. F. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108366
Multiplexed Engineering of Salmonella Typhimurium for Targeted Cancer Therapies
Liu, X., Zhang, P. D., Chen, D., Xu, S., Wu, S. S., & Qiao, J. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.6c00119 · Cited by 2
Smail, S. W., Flaih, A. H., Ismail, B. A., Ahmed, A. A., Bapir, A. A., Qadir, F. A., & Janson, C. (2026) · Immuno · doi:10.3390/immuno6020034
Synthetic Biology for Diagnosis and Therapy of Genetic Disorders
Zala, D., Banerjee, S., Mehta, A., & Tiwari, A. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-3957-4_43
Design and Implementation of Synthetic Oscillators
Kirov, B., & Peykov, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-3957-4_5
Khambhati, K., Panchal, K., & Singh, V. (2026) · Springer eBooks · doi:10.1007/978-981-95-3957-4_1
Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology
Liu, X., Zhang, H., Du, R., Liu, Z., Ren, Y., & Yang, X. S. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2026.2683171 · Cited by 1
Development strategies for engineered live biotherapeutic products for metabolic diseases
Yun, S., Choi, K.-S., Min, H., Jo, Y. K., & Jang, S. (2026) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2026.2653692 · Cited by 1
Engineered bacteria in disease diagnosis and therapy: A synthetic biology perspective
Shen, Y., Lu, S.-M., Yang, L., Li, Y., Zhang, Y., & Liang, L. (2026) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2026.04.028 · Cited by 1
Externally Controllable Multicellular Molecular Communication
Zhu, J., Inoko, T., Koujin, T., Kobayashi, S., & Nakano, T. (2026) · IEEE Nanotechnology Magazine · doi:10.1109/mnano.2026.3706280
Rouanne, M., Chen, N., Mariuzza, D. L., Yang, Z., Li, F., Santos, K. D. L., Savage, T. M., Vincent, R. L., Mendelsohn, C. L., Danino, T., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adv7600 · Cited by 3
Self-citationJinhu, G., Li, Y., Yang, Y., & Wang, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1878878
Kong, Z., & Wang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1891408 · Cited by 2
Guan, L., 孙钦晓, Jiang, H., Liang, D., Zhang, S., Huang, L., Guan, X., Hu, X., & Chen, G. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103550
Bi, S., Wang, M., Guan, Q., Wang, Y., Liu, R., Zhang, J., Li, M., Liu, Q., Wang, P., Zhang, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76647-5
A diversified consortium of engineered biosensors enables multi-target quantification
Chiang, A. J., Csicsery, N., O’Laughlin, R., Baumgart, L. A., Stasiowski, E., Nguyen, P., Doughty, A. C. V., Ashraf, M., Mink, R., Olson, E. C., et al. (2026) · Cell Systems · doi:10.1016/j.cels.2026.101702 · Cited by 1
Self-citationEnterococcus and cancer: from mechanistic insights to clinical translation
Feng, H., Huang, X., Zhuang, Y., Pu, L., Dong, R., & Ren, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1882184
Zhou, H., He, J., Chen, J., Ge, S., Yü, P., & Zhang, W. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2720162 · Cited by 1
Surface display of co-stimulatory ligand B7H2 on engineered bacteria enhances tumor immunotherapy
Feng, Q., Wang, C., Li, Z., Sheng, D., Shi, S., Liu, J., & Chen, B. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103016
The progress and perspective of tumor immunotherapy
Li, X., Song, Y., Xiao, L., Tong, F., Yu, M., Gao, H., & Ran, R. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.113390
Oncolytic bacteria therapy for malignant glioma
Li, F., Zhao, J., Ji, A., Zhao, J., & Li, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1951763
Zheng, N., Tang, Z., Yang, G., Deng, L., Zhao, Q., Zhao, Y., Zhang, J., Wang, X., Chai, Y., Chen, Y., et al. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.09.004
Lu, J., Xuan, M., Yu, L., Xie, Z., Chu, Q., Wei, S., Wang, T., Xue, C., & Li, L. (2026) · MedComm · doi:10.1002/mco2.70994
Genetic principles enabling the creation of bacteria-based therapeutics
Williams, A. B., Groseclose, T. M., Holec, S. A. M., Newman, D., Mora, D. S. O., & Linke, L. (2026) · Genetics · doi:10.1093/genetics/iyag235 · Cited by 1
Sun, W., Liu, H., Shao, A., Li, R., Ma, W., Zheng, M., Yan, S., Liu, S., Wu, M., & Sun, D. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1970221
Gut microbiota: A key modulator of individualized efficacy and toxicity in cancer therapy
Hou, X., Chen, K., Ran, L., Pu, R., Tong, R., Li, P., Liu, K., Du, H., Liu, Y., & Hou, X. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101802
Rathod, B., & Puri, S. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108987
Xing, S., 张佳宇, Wang, S., Hao, Y., Huang, D., Hao, M., Bao, W., Qu, X., Chi, Y., & Li, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1923822
Abu‐Ghosh, S. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.109068
Cossu, C., Adamo, M., Lorenzo, A. D., & Conti, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1944056
Hou, X., Guo, P., Wang, S., Yuan, Y., Wei, W., & Zheng, D. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100599
Dunga, K. E., Izah, S. C., Aseibai, E. R., Ogwu, M. C., Promise, V. I., Etim, N. G., & Ohanusi, I. N. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1966586
Engineered live biotherapeutic products: design decisions, failure modes, and clinical translation
Shen, S., Zhao, J., & Gao, H. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.2002085
Zhao, N., Zhang, H., Pang, Y., Zhu, L., Liu, Q., Zhang, Z., Shen, L., He, Y., & Lin, S. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00840-x
Communication Circuits in Bacteria
Doughty, A. C. V., Chiang, A. J., & Hasty, J. (2026) · SynBio · doi:10.3390/synbio4040020
Self-citationSun, S., Hu, R., Zhai, X., Bai, R., Guo, J., Zhou, T., Yang, T., Zeng, Q., Zhang, Y., Yu, J., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115459
Microbes as a programmable toolbox for cancer diagnosis, monitoring, and theranostics
Calejo, I., & Canadas, R. F. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.09.023
Bakhsh, M., Kwon, J., Haq, I. U., Riaz, J., Kim, C. M., & Lee, J. H. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.109078
Elmetwalli, A., Algehainy, N. A., Altemani, F. H., Alanazi, M. A., & Altemani, A. H. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127586
Metadata
- Authors
- Din, M. O., Danino, T., Prindle, A., Skalak, M., Selimkhanov, J., Allen, K., Julio, E., Atolia, E., Tsimring, L. S., Bhatia, S. N., & Hasty, J.
- Affiliations
- University of California San Diego (US)
- Massachusetts Institute of Technology (US)
- Broad Institute (US)
- Corresponding author
- Hasty, Jeff
- ORCID
- Venue
- Nature
- Published
- 2016-07-20
- Volume
- 536
- Issue
- 7614
- Pages
- 81-85
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5048415
- OpenAlex
- W2480697384
- Cited by
- 784
- References
- 31
- Citations by year
- 2026: 97 · 2025: 107 · 2024: 95 · 2023: 87 · 2022: 73 · 2021: 71 · 2020: 82 · 2019: 59 · 2018: 55 · 2017: 43 · 2016: 12
- FWCI
- 49.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- PMC
- Funders
- Howard Hughes Medical Institute
- University of California, San Diego
- National Cancer Institute (K99CA197649, R00CA197649, DP1CA174420, P30CA014051)
- National Institute of General Medical Sciences (P50GM085764, R01GM069811)
- National Institute of Environmental Health Sciences (P30ES002109)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- bacterial lysis, quorum sensing, synthetic biology, Salmonella, pulsatile drug delivery, cancer therapy, colorectal cancer, liver metastasis, bacterial population dynamics, luminescent reporter, combination chemotherapy, oral administration, living therapeutics
- MeSH terms
- Administration, Oral, Animals, Bacteriolysis, Computer Simulation, Female, Liver Neoplasms, Neoplasm Metastasis, Neoplasm Transplantation, Salmonella, Transplantation, Isogeneic, Colorectal Neoplasms, Drug Delivery Systems, Coculture Techniques, Luminescence, Mice, Quorum Sensing, Synthetic Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.